SAR-260301

SAR-260301 is an orally available and selective PI3Kβ inhibitor with an IC50 of 23 nM[1][2].

Product Specifications

CAS Number

[1260612-13-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

PI3K

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/SAR-260301.html

Purity

99.95

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1N=C(CC(N2[C@@H](C)CC3=C2C=CC=C3)=O)NC(N4CCOCC4)=C1

Molecular Formula

C19H22N4O3

Molecular Weight

354.40

Precautions

H302, H315, H319, H335

References & Citations

[1]Certal V, et al. Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN) -deficient cancers. J Med Chem. 2014 Feb 13;57 (3) :903-20.|[2]Bonnevaux H, et al. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor. Mol Cancer Ther. 2016 Jul;15 (7) :1460-71.